<DOC>
	<DOCNO>NCT02429466</DOCNO>
	<brief_summary>This open-label , single arm , Phase I dose escalation study subject refractory germ cell tumor ( rGCT ) . This phase I evaluate safety efficacy SGI-110 combination cisplatin subject rGCT . The primary objective determine maximum tolerate dose ( MTD ) SGI-110 use prior cisplatin . A total 15 subject enrol study Indiana University Simon Cancer Center .</brief_summary>
	<brief_title>Study Hypomethylating Drug SGI-110 Plus Cisplatin Relapsed Refractory Germ Cell Tumors</brief_title>
	<detailed_description>Primary Objective : To assess safety toxicity SGI-110 plus cisplatin include dose limiting toxicity ( DLT ) determine Maximum tolerate dose ( MTD ) Secondary Objective : To assess efficacy SGI-110 resume sensitivity cisplatin refractory GCT Correlative Objective : To evaluate pharmacodynamic activity SGI-110 Evaluate miRNA biomarkers serum day 1 cycle 1-6 Intervention Mode Delivery : SGI-110 give subcutaneously , daily , 30 mg/m2 day ( 1-5 ) follow cisplatin 100mg/m2 day 8 every 4 week . Duration Intervention Evaluation : Treatment continue maximum 6 cycle disease progression unacceptable toxicity whichever occur first . Subjects respond therapy without major toxicty would allow continue single agent SGI-110 MTD 4-6 cycle combination therapy disease progression . Subjects follow last cycle every 2 month 1st year , every 4 month thereafter death ( expect overall survival less 12 month ) .</detailed_description>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Testicular Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>1 . ≥ 18 year old time inform consent 2 . Written inform consent HIPAA authorization release personal health information . 3 . Subjects willing able comply protocol study procedure include willingness undergo tumor biopsy tumor cell therapy Cycle 1 , Day 1 , Day 8 ( cisplatin dose ) clinically safely feasible . 4 . Subjects histologically serologically confirm diagnosis recurrent germ cell tumor . 5 . Subjects platinumresistant disease . There limit number prior treatment regimen . 6 . Subjects must prior high dose chemotherapy ( HDCT ) treatment indicate . 7 . Subjects measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 elevate Tumor marker ( hCG AFP ) . Note : patient without measurable disease allow study long clearly rise tumor marker exempt biopsy . 8 . Subjects ECOG performance status 02 . 9 . Subjects must least 3 week last chemotherapy . 10 . Females childbearing potential must pregnant breastfeeding . Male female patient reproductive potential must agree use two form highly effective contraception screen visit 30 day last dose study drug . Acceptable form effective contraception include : Oral , injected implant hormonal method contraception . Placement intrauterine device ( IUD ) intrauterine system ( IUS ) . Barrier method contraception : Condom Occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository . Male sterilization ( appropriate postvasectomy documentation absence sperm ejaculate ) . True abstinence : When line prefer usual lifestyle subject . [ Periodic abstinence ( e.g. , calendar , ovulation , symptothermal , postovulation method ) withdrawal acceptable method contraception . ] Pregnancy test females childbearing potential require ; must serum screen post treatment safety assessment visit . A positive urine pregnancy test must confirm serum pregnancy test pelvic US since NSGCT may secrete betahCG cause false positive pregnancy . A pelvic US need repeat cycle unless treat physician think necessary . 11 . The following laboratory value must obtain within 14 day prior registration protocol therapy . Absolute neutrophil count ≥ 1500 cells/mm3 Hemoglobin ( Hgb ) ≥ 8 g/dL Platelets count ≥ 100,000 cells/mm3 Serum creatinine level ≤ 1.5 mg/dl calculate ( CockcroftGault formula ) measure creatinine clearance ≥ 50 mL/min Bilirubin ≤ 2 x ULN Aspartate aminotransferase ( AST , SGOT ) ≤ 3 x ULN Alanine aminotransferase ( ALT , SGPT ) ≤ 3 x ULN 1 . Active central nervous system ( CNS ) metastases . Subjects neurological symptom undergo head CT scan brain MRI exclude brain metastasis , discretion treat physician . NOTE : A subject prior brain metastasis may consider complete treatment brain metastasis , long require corticosteroid , asymptomatic . 2 . Treatment investigational agent within 30 day prior registration protocol therapy . 3 . Concurrent participation clinical trial involve another investigational agent . 4 . Subjects Grade 2 great neuropathy . 5 . Subjects lifethreatening illness , medical condition organ system dysfunction , reason , Investigator 's opinion , could compromise subject 's safety , interfere compromise integrity study outcomes include incomplete recovery acute effect prior antineoplastic therapy . 6 . Pregnancy breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>testicular germ cell tumor</keyword>
	<keyword>ovarian germ cell tumor</keyword>
	<keyword>platinum refractory</keyword>
	<keyword>cisplatin</keyword>
	<keyword>SGI110</keyword>
	<keyword>Guadecitabine</keyword>
</DOC>